Beam Therapeutics (BEAM) said Monday it has priced an underwritten offering of 16.2 million shares at $28.48 per share, and pre-funded warrants to purchase 1.4 million shares at $28.47 per pre-funded warrant.
Gross proceeds from the offering, expected to close Tuesday, are anticipated to be about $500.0 million, the company said.
Beam said intends to use net proceeds from the offering for technology advancement, research and development, and other general corporate purposes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。